Goldman Sachs gives its verdict on the CSL share price

Where next for CSL's shares?

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been on a decent run over the last couple of months.

Since the middle of June, the biotherapeutics company's shares have risen a sizeable 14%.

This compares to a gain of approximately 6% for the benchmark ASX 200 index.

Why is the CSL share price on a roll?

Investors have been bidding the CSL share price higher due to the release of very positive industry data.

That data shows that plasma collection levels are now back to pre-COVID levels in the United States at long last.

This is a big positive for CSL as plasma is a key ingredient in many of its most lucrative therapies. When it was in short supply, the company was paying more than normal for donations, which was putting pressure on its margins. With supply now back to normal and collection prices reducing, CSL should soon start to see its margins improve again.

All in all, the general consensus is that CSL is now over the worst of its issues, and it is onwards and upwards from here. But will it be onwards and upwards for the CSL share price?

Where are its shares heading?

According to a note out of Goldman Sachs, its analysts believe CSL's shares may be close to peaking for the time being.

This morning the broker has resumed coverage on the company with a neutral rating and $307.00 price target. This implies potential upside of just 5% from the current CSL share price of $292.35.

Goldman believes that the company's shares are about fair value now based on historic earnings multiples. It explained:

Valuation of 34x NTM P/E has now recovered to the 5yr avg, and is back above the 10yr (29x). We believe risk-reward is once again well-balanced, and reinstate our rating at Neutral, with a 12-month TP of A$307.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Broker Notes

1 ASX 300 stock just upgraded by brokers (and 2 downgraded)

Here's the latest ratings changes.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Bell Potter names the best ASX 200 stocks to buy in November

These quality stocks are top picks in November according to the broker.

Read more »

A man sees some good news on his phone and gives a little cheer.
Broker Notes

2 ASX 300 shares to buy now for 50% to 80% returns

These shares could have big return potential according to brokers. Let's see what they are saying.

Read more »

Broker looking at the share price.
Broker Notes

3 ASX All Ords shares just got BIG upgrades from top brokers

Leading brokers believe these ASX All Ords stocks could fly higher into 2025.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

Up 45% in 2024! Can ResMed shares keep rising?

Is this high-flying stock destined to keep soaring? Let's see what one broker is saying.

Read more »

A miner stands in front oh an excavator at a mine site
Broker Notes

Broker says buy the dip on ASX 200 uranium share with 69% upside

Shaw and Partners says this ASX uranium stock is trading at an attractive price point right now.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

Bell Potter says these ASX stocks are top buys

Let's see why the broker is feeling so bullish on these names.

Read more »